Workflow
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
REGNRegeneron(REGN) GlobeNewswire·2025-01-13 11:05

Strategic Collaboration and Investment - Regeneron Pharmaceuticals announced a strategic collaboration with Truveta Inc and its collective of US health systems to advance innovation and data-driven discovery across life sciences, public health, and healthcare delivery [1] - Regeneron will invest 119.5millioninTruveta′sSeriesCfinancingroundandcollaboratetolaunchtheTruvetaGenomeProject,aimingtosequenceuptotenmillionadditionalde−identifiedpatientvolunteerswithlinkedelectronichealthrecords(EHRs)[1]−TheTruvetaGenomeProjectwillextendRegeneron′sDNAsequence−linkedhealthcaredatabase,whichcurrentlyincludesnearlythreemillionde−identifiedpatientvolunteers,tounlockinsightsintohowgeneticsimpacthealthandpotentiallyleadtonewgenetic−basedtherapies[1][4]ProjectGoalsandImpact−TheTruvetaGenomeProjectaimstodramaticallyacceleratethediscoveryofnewgenetics−baseddrugtargetsandtherapies,whileempoweringhealthcareanalyticsandmanagement[4]−Theprojectwillintegrategenotypicdatafromuptotenmillionde−identifiedconsentedvolunteerswithTruveta′smedicaldatabase,representingover120millionpatientsacross30healthsystems,toyieldactionableinsightsfordrugdevelopmentandhealthcaredelivery[3]−Regeneron′sRGCwillhaveexclusiverightstoperformallresearch−relatedsequencingonsamplescollectedunderthecollaborationandaccesstode−identifiedEHRdataprovidedbystudyparticipants[6][7]IndustryandScientificAdvancements−ThecollaborationcombinesRegeneron′sexpertiseingeneticsanddrugdevelopmentwithTruveta′sextensivephenotypicdataandcollaborationofleadingUShealthsystemstocreatea′BigData′resourcefornext−generationdrugdiscoveryandhealthcaremanagement[8]−Regeneron′sRGChasalreadyidentifieddozensofgenetic−baseddrugtargetsforconditionssuchaschronicliverdisease,obesity,cancer,andneurodegenerativeconditions,leadingtomultipleclinical−stagemedicines[3]−IlluminaInc,agloballeaderinDNAsequencing,willalsoinvest119.5 million in Truveta's Series C financing round and collaborate to launch the Truveta Genome Project, aiming to sequence up to ten million additional de-identified patient volunteers with linked electronic health records (EHRs) [1] - The Truveta Genome Project will extend Regeneron's DNA sequence-linked healthcare database, which currently includes nearly three million de-identified patient volunteers, to unlock insights into how genetics impact health and potentially lead to new genetic-based therapies [1][4] Project Goals and Impact - The Truveta Genome Project aims to dramatically accelerate the discovery of new genetics-based drug targets and therapies, while empowering healthcare analytics and management [4] - The project will integrate genotypic data from up to ten million de-identified consented volunteers with Truveta's medical database, representing over 120 million patients across 30 health systems, to yield actionable insights for drug development and healthcare delivery [3] - Regeneron's RGC will have exclusive rights to perform all research-related sequencing on samples collected under the collaboration and access to de-identified EHR data provided by study participants [6][7] Industry and Scientific Advancements - The collaboration combines Regeneron's expertise in genetics and drug development with Truveta's extensive phenotypic data and collaboration of leading US health systems to create a 'Big Data' resource for next-generation drug discovery and healthcare management [8] - Regeneron's RGC has already identified dozens of genetic-based drug targets for conditions such as chronic liver disease, obesity, cancer, and neurodegenerative conditions, leading to multiple clinical-stage medicines [3] - Illumina Inc, a global leader in DNA sequencing, will also invest 20 million in Truveta's Series C financing round to support the Truveta Genome Project [2] Company Background - Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for serious diseases, with a focus on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [9] - The company leverages proprietary technologies like VelociSuite to produce optimized fully human antibodies and new classes of bispecific antibodies, shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center [10] - The Regeneron Genetics Center (RGC) is a genomic research initiative that has harnessed human genetics for over a decade to discover new medicines, validate research programs, and optimize clinical trials, with a database of over 2.6 million sequenced exomes [12]